Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time.

Biotechnology

Adaptive Phage Therapeutics

Joseph Fackler

Rob Casper

Jacqueline Rivera

Carl R. Merril

Eric Zirkle

Emae Lee-Voritskul, CPA

Edward Fang

The executive team at Adaptive Phage Therapeutics has a history of experience in the fields of immunology, microbiology, and infectious disease. The team is led by Chief Medical Officer, who has a background in Chemistry from William & Mary and a Fellowship in Infectious Disease and Geographic Medicine from the University of Maryland School of Medicine. The team also includes a Vice President of Clinical Development and a Senior Medical Advisor, both with degrees in Microbiology and Immunology from the University of Maryland School of Medicine.

CEO and Executive Team

Leadership Team

Board of Directors

CEO and Executive Team

About

Team members

Other teams at Adaptive Phage Therapeutics

Leadership Team

Board of Directors